Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - piroxicam betadex 191.2mg equivalent to 20 mg piroxicam - oral granules - 20 mg - active: piroxicam betadex 191.2mg equivalent to 20 mg piroxicam excipient: aspartame colloidal silicon dioxide sorbitol

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

chiesi limited - piroxicam betadex - tablets effervescent - 20mg milligram

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yvette is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yvette for pmdd was not assessed beyond 3 cycles. yvette has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - leah is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of leah for pmdd was not assessed beyond 3 cycles. leah has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine betadex complex, quantity: 17.1 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: betadex; magnesium stearate; crospovidone; colloidal anhydrous silica - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thus facilitating smoking cessation in smokers motivated to quit.

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg; drospirenone 3 mg - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate - drospirenone and ethinylestradiol

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg (light pink tablet); drospirenone 3 mg (light pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate; placebo - drospirenone and ethinylestradiol

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

impexeco - drospirenone; ethinylestradiol betadex clathrate - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate - drospirenone and ethinylestradiol